What’s new from Toby Oncology

• News

TOBY Selected to Present at AUA 2026 Innovation Nexus Forum

TOBY has been selected by the American Urological Association (AUA) to present at the 2026 AUA Innovation Nexus Forum, taking place on May 14, 2026, in Washington, DC. The AUA […]

• News

TOBY Appoints Healthcare Industry Leader Dan Collins as Advisor to the Board

Collins will advise the Board of Directors and executive leadership on corporate growth, fundraising, commercialization, and strategic partnerships as the company advances its urine-based volatile organic compound (VOC) test for early multi-cancer detection, designs future studies, and prepares for its next stage of expansion.

• News

TOBY Appoints Healthcare Leader Matthew Collier as Independent Director

As an independent director, Collier will provide objective oversight and strategic guidance as TOBY advances its groundbreaking technology toward commercialization.

• Press

TOBY receives FDA Breakthrough Device Designation (April 2025)

TOBY's test provides a painless, low-cost alternative—analyzing volatile organic compounds (VOCs) in a single urine sample using gas chromatography–mass spectrometry and proprietary AI to generate a real-time cancer risk score.

• News

TOBY completes Nashville Entrepreneur Center’s Project Healthcare Accelerator

Project Healthcare, now in its seventh year, is designed to support high-growth healthcare startups by offering a tailored curriculum and connections to Nashville's extensive network of healthcare organizations, including seven of the nation's largest health systems.

• News

TOBY Urine Test completes participation in 2025 Mayo Clinic and ASU Alliance for Health Care MedTech Accelerator

The Mayo Clinic and Arizona State University MedTech Accelerator supports early-stage medical technology companies through access to clinical, academic, and commercial resources.